Assessment of Knowledge and Attitude of Breast and Ovarian Cancer Patients Regarding Hereditary Breast-Ovarian Cancer Syndrome at a Tertiary Cancer Institute: A Cross-Sectional Observational Study

 

 Permissions and Reprints

Abstract

Introduction Hereditary breast and ovarian cancer (HBOC) syndrome affects a significant proportion of our breast and ovarian cancer patients. Mutations in genes, for example, BRCA1 and 2, confer a high risk of acquiring certain malignancies, including breast cancer in both men and women, and ovarian cancer in women. Mutation carriers provide a unique opportunity for healthcare professionals to intensively screen and detect malignancy at an early and curable stage. But, patient awareness and acceptance are the keys to the success of these strategies.

Objective There is a need to assess the awareness of the patients in this field as the patients come from varied backgrounds, and differ in their socioeconomic profiles, educational backdrop, and cultures. In this study, done prior to establishing our cancer genetics clinic, we evaluated the knowledge and attitude toward HBOC in patients with breast cancer and ovarian cancer.

Materials and Methods This cross-sectional observational study was conducted on patients registered in IRCH-AIIMS, who has a diagnosis of breast cancer or ovarian cancer using a self-administered questionnaire based on knowledge and attitude. The sample population included 84 women aged between 25 and 80 years. A binary response was given to knowledge questions, whereas a categorical response was given to attitude questions. The overall data was computed using STATA v13 software.

Results According to the findings of the study, 39.3% (5.11/13) of the patients were aware of hereditary cancer. Knowledge among the targeted population was poor, but 72.1% (37.5/52) of the population had a neutral attitude toward learning more about hereditary cancer tests. Only 23/84 (27%) people had heard of genetic counseling. Seventy of eighty-four (83%) patients agreed that they would opt for a genetic test if indicated. While 60/84 (72%) of the population wanted to interact with a counselor over a telephonic call, only 41/84 (49%) wanted to interact in person.

Conclusion We concluded from the study that breast and ovarian cancer patients in our clinic have little understanding of HBOC syndrome but have a neutral attitude toward learning more about it.

Ethical Approval

The study was approved by the Institute Ethical Committee vide Letter No. IEC-186/06.04.2018, RP-47/2018.

Availability of Data and Material

Data regarding this study will be available from the corresponding author (R.P.) at reasonable request.

Authors' Contributions

R.P., S.D., L.K. conceptualized the study, S.V. collected data, S.M., R.P., S.K., A.G., and A.B. analyzed data, and R.P. and S.M. drafted the manuscript. The final manuscript was reviewed and edited by all authors.

Publication History

Article published online:
12 May 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

• References

• 1 Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health 2019; 11: 287-299
  CrossrefPubMedGoogle Scholar
• 2 Malhotra H, Kowtal P, Mehra N. et al. Genetic counseling, testing, and management of HBOC in India: an expert consensus document from Indian Society of Medical and Pediatric Oncology. JCO Glob Oncol 2020; 6: 991-1008
  CrossrefPubMedGoogle Scholar
• 3 Kadri MSN, Patel KM, Bhargava PA. et al. Mutational landscape for Indian hereditary breast and ovarian cancer cohort suggests need for identifying population specific genes and biomarkers for screening. Front Oncol 2021; 10: 568786
  CrossrefPubMedGoogle Scholar
• 4 Gupta S, Rajappa S, Advani S. et al. Prevalence of BRCA1 and BRCA2 mutations among patients with ovarian, primary peritoneal, and fallopian tube cancer in India: a multicenter cross-sectional study. JCO Glob Oncol 2021; 7: 849-861
  CrossrefPubMedGoogle Scholar
• 5 Singh J, Thota N, Singh S. et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat 2018; 170 (01) 189-196
  CrossrefPubMedGoogle Scholar
• 6 Mittal A, Deo SVS, Gogia A. et al. Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India. Ecancermedicalscience 2022; 16: 1434
  CrossrefPubMedGoogle Scholar
• 7 Paradiso AV, Digennaro M, Patruno M, De Summa S, Tommasi S, Berindan-Neagoe I. BRCA germline mutation test for all woman with ovarian cancer?. BMC Cancer 2019; 19 (01) 641
  CrossrefPubMedGoogle Scholar
• 8 Yadav S, Hu C, Hart SN. et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol 2020; 38 (13) 1409-1418
  CrossrefPubMedGoogle Scholar
• 9 Mannan AU, Singh J, Lakshmikeshava R. et al. Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India. J Hum Genet 2016; 61 (06) 515-522
  CrossrefPubMedGoogle Scholar
• 10 Petrova D, Cruz M, Sánchez MJ. BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications. Breast 2022; 61: 66-76
  CrossrefPubMedGoogle Scholar
• 11 Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev 2018; 4 (04) CD002748
  CrossrefPubMedGoogle Scholar
• 12 Puski A, Hovick S, Senter L, Toland AE. Involvement and influence of healthcare providers, family members, and other mutation carriers in the cancer risk management decision-making process of BRCA1 and BRCA2 mutation carriers. J Genet Couns 2018; 27 (05) 1291-1301
  CrossrefPubMedGoogle Scholar
• 13 Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer. Int J Clin Oncol 2018; 23 (01) 45-51
  CrossrefPubMedGoogle Scholar
• 14 Singh S, Shrivastava JP, Dwivedi A. Breast cancer screening existence in India: a nonexisting reality. Indian J Med Paediatr Oncol 2015; 36 (04) 207-209
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Ormond KE, Laurino MY, Barlow-Stewart K. et al. Genetic counseling globally: where are we now?. Am J Med Genet C Semin Med Genet 2018; 178 (01) 98-107
  CrossrefPubMedGoogle Scholar
• 16 Hann KEJ, Freeman M, Fraser L. et al; PROMISE study team. Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review. BMC Public Health 2017; 17 (01) 503
  CrossrefPubMedGoogle Scholar
• 17 Kwong A, Shin VY, Ho JC. et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet 2016; 53 (01) 15-23
  CrossrefPubMedGoogle Scholar
• 18 Khatak S, Wadhwa N, Pandey AK. et al. Public perception of genetic counseling in India: opening mind eyes. Shodh Sarita 2020; 7: 104-111
  Google Scholar
• 19 Singh M, Prasad CP, Singh TD, Kumar L. Cancer research in India: challenges & opportunities. Indian J Med Res 2018; 148 (04) 362-365
  CrossrefPubMedGoogle Scholar
• 20 Monaghesh E, Hajizadeh A. The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence. BMC Public Health 2020; 20 (01) 1193
  CrossrefPubMedGoogle Scholar

• Supplementary Material